Related Experiment Videos
Premedication strategy for weekly paclitaxel.
Justin Quock1, Gilland Dea, Michael Tanaka
1University of California, Davis Cancer Center, VA Northern California Health Care System, 4501 X Street, Sacramento, CA 95817, USA.
Cancer Investigation
|August 29, 2002
Summary
This study suggests a new premedication strategy can safely reduce hypersensitivity reactions (HSRs) to paclitaxel, potentially eliminating the need for frequent premedications in many patients receiving weekly treatments.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Paclitaxel hypersensitivity reactions (HSRs) are common, often managed with frequent premedications like dexamethasone and histamine antagonists.
- These frequent premedications can lead to additional side effects and increased healthcare costs.
Purpose of the Study:
- To analyze the incidence of HSRs to paclitaxel administered every 3-4 weeks.
- To develop and evaluate a treatment algorithm to eliminate premedications in patients receiving weekly paclitaxel.
Main Methods:
- Retrospective analysis of HSRs in 358 patients receiving paclitaxel (135-225 mg/m2) every 3-4 weeks over 5 years.
- Development of a novel premedication schema for weekly paclitaxel (50-90 mg/m2/week): initial dose with dexamethasone, diphenhydramine, and cimetidine, with subsequent doses omitted if no HSRs occurred.
Main Results:
- HSRs occurred in 4% of patients during the first paclitaxel cycle; most could be retreated successfully without recurrent reactions.
- The new premedication strategy was applied to 30 patients receiving weekly paclitaxel, resulting in no observed HSRs during initial or subsequent administrations.
Conclusions:
- The developed premedication strategy is feasible for weekly paclitaxel administration.
- This approach warrants further investigation for its potential to reduce side effects and costs associated with HSR prophylaxis.